Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Sales of Investments
Cash received from selling or redeeming investments.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Sales of Investments · Q2 FY2026 · quarter ended Jun 2026
Sales of investments of $34.9M in Q2 FY2026
Q2 FY2026 sales of investments was $34.9M.
Context
- Sales of investments amounted to 11166.7% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 150.75M USD
- Year-over-year change
- +1784.4%
- 1-year CAGR
- +1784.4%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 150.75M | +1784.4% |
| FY2024 | 2024-12-31 | 8M | — |
Sales of Investments vs competitors
How ATTO compares with its peers on the latest reported figures
- ATTO's FY2025 sales of investments of $150.75M is the 5th largest of the 10 companies compared; the peer median is $94.1M.
- Its year-over-year change of +1784.4% is the highest of 8, against a peer median of +65.8%.
- Sales of investments amounts to 11166.7% of revenue for ATTO, versus a peer median of 947.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $555.15M | +110.1% | +46.4% | 7504.0% |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $405.29M | +102.6% | — | — |
| LTM Mar 2026 | $382.74M | +65.8% | +261.7% | — | |
| LTM Mar 2026 | $322.1M | -33.7% | +1.3% | 138.6% | |
| FY2025 | $150.75M | +1784.4% | — | 11166.7% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $94.1M | — | — | 941.0% |
| LTM Mar 2026 | $79.8M | -19.5% | -20.6% | 953.7% | |
| FY2025 | $39.95M | +216.4% | +5.0% | 62417.2% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | $0 | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ATTO) | $94.1M | +65.8% | +5.0% | 947.4% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (45.05M) | (60.9M) |
| Depreciation & Amortization | 313K | 804K |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 1.54M | 276K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 1.72M | 180K |
| Other Working Capital | (181K) | 96K |
| Other Non-Cash Items | 8.16M | 619K |
| Operating Cash Flow | (35.04M) | (59.2M) |
| Capital Expenditures | (1.77M) | (2.31M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (46.03M) | (221.89M) |
| Sales of Investments | 8M | 150.75M |
| Other Investing Activities | 0 | 0 |
| Investing Cash Flow | (39.8M) | (73.46M) |
| Debt Repayment | (171K) | 0 |
| Common Stock Issued | 82.92M | 142.01M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0 | 0 |
| Financing Cash Flow | 82.75M | 142.01M |
| Effect of Forex Changes | 22.73M | 203K |
| Net Change in Cash | 30.63M | 9.56M |
| Free Cash Flow | (36.81M) | (61.51M) |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.